Detailed Narrative
Renal Segment Becomes a Major Growth Engine
The Renal business has emerged as a standout performer, growing at 56% in the first nine months of FY25. Management expects this trajectory to continue as they replace imported products in India, where they are currently the only local producer of certain renal consumables. The company is targeting a 20-25% market share by 2030, supported by increased government reimbursement rates for dialysis under the National Dialysis Program.
Strategic Entry into High-Value Cardiology
Poly Medicure has received the CDSCO license for Drug-Eluting Stents (DES) and plans to commercialize the product immediately. Unlike competitors who import components, Polymed will manufacture the stent and the balloon in-house, which management believes will provide a significant cost and maneuverability advantage. This move into Class 3 implantable devices represents a shift toward higher-priced, longer-dwelling medical products.
Massive CAPEX Cycle Funded by Internal Accruals
The company invested ₹222 crores in CAPEX during the first nine months of FY25, primarily through internal accruals. A new large-scale plant in Palwal, Haryana, is under construction and expected to be commissioned by mid-2026. Total planned spending for three new plants is estimated at ₹400-500 crores over the next 18-20 months, which will be funded using the ₹1,000 crore QIP proceeds.
Domestic Recovery and Export Resilience
After a slow first quarter, the domestic business rebounded with 23.8% growth in Q3, bringing the 9M growth to 16.7%. Management is confident of exceeding 20% domestic growth for the full year. Exports remain the dominant revenue contributor at approximately 70%, with Europe showing strong 30% growth in the nine-month period, driven by leadership in the infusion therapy category.
Margin Expansion Through Operational Leverage
Management has guided for a 100-150 bps improvement in EBITDA margins for FY25, having already achieved a 95 bps improvement in the first nine months. They believe a 50-100 bps annual margin expansion is sustainable over the next 4-5 years. This will be driven by operational efficiencies as new sales teams (64 people added in 9M) reach full productivity and high-margin new verticals like oncology and cardiology scale up.